EGFR and non-small cell lung carcinoma: In contrast, a predictive and prognostic impact of TP53 mutations has been hard to discern in case of EGFR/ALK-negative NSCLC [52], in which the much higher number of genetic alterations at baseline [53] presumably obscures the effect of TP53 status and dilutes the consequences of genetic instability [39].